Alexandria, VA. (June, 22, 2022)–  Bluesight, the leading automation vendor in Medication Intelligence™ was reviewed in KLAS’s Drug Diversion Monitoring Report for its diversion monitoring software, ControlCheck. Drug diversion monitoring continues to be a high-priority issue for hospital pharmacy departments across the U.S. The report analyzes the performance of several vendors and highlights those who consistently deliver key insights and analytics that help organizations prevent and identify drug diversion. 

Bluesight is the market share leader and a top performing vendor in this report, with Bluesight customers consistently seeing success in tangible outcomes. Earlier this year, Bluesight was ranked Best in KLAS for drug diversion monitoring for the third consecutive year.

In the report, BLuesight’s ControlCheck ranked the highest under the loyalty pillar which gauges customers satisfaction and likelihood of recommending the product to others.

Participants ranked ControlCheck overwhelmingly above market average when asked if ControlCheck was part of their long-term plans. Respondents also ranked Bluesight highly for overall satisfaction and applauded the platform for its ease of use, allowing for customers to save time and readily identify potential cases of diversion. 

“The vendor is very proactive. They look to their customers’ needs. BLuesight is very open to our suggestions, and they mold themselves to meet our needs. They are doing a pretty good job of listening to our concerns right now.” said one respondent. It is evident customers appreciate Bluesight’s regular meetings with customers to offer guidance and solicit feedback.

Additionally, respondents say product strengths include automatic daily benchmarking and reporting and the auditing process; these capabilities, along with consistent meetings with the vendor and proactive vendor guidance, have driven customer success.

A director noted “One tangible outcome is the amount of time the system saves. I used to audit 100% of certain tabs due to issues that we identified. Auditing those tabs would take me anywhere between a half hour and an hour every day. I would have to run a hard report and then manually go into every chart. Now, when I open up the product, I know whether something isn’t documented. There are some days when I have nothing to audit, and there are some days where I have a couple of things I need to look into. But the system saves a lot of time. The time savings are applied across every controlled substance, not just the specific ones. That is a huge tangible outcome.” 

“When it comes to a diversion monitoring solution, tangible outcomes are always our number one focus.” said Kevin MacDonald, co-founder and CEO of BLuesight. “We look to empower our customers to make informed decisions and the KLAS report highlights the value our customers are receiving.”

You can access the report here.

To learn more about KLAS, please visit http://www.klasresearch.com.